Related Experiment Video
Updated: Oct 10, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy
Yunjian Yu1, Jie Li1, Boyi Song1
1Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, 300071, PR China.
Abstract:
Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a series of drawbacks. Herein, an all synthetic nanoparticle with PD-L1 blockade capability is developed for cancer photothermal-immunotherapy. The polymeric nanoparticle integrates photothermal treatment, antitumor vaccination, and PD-1/PD-L1 blockade in a single system to augment the antitumor efficacy. In a CT26 bilateral tumor model, intravenously injected nanoparticles accumulate in tumor sites and mediate strong photothermal effects, eradicate the NIR treated primary tumors and elicit strong antitumor immunity by inducing immunogenic cell death (ICD). Growth of the untreated distant tumors is also suppressed due to the synergies of systemic antitumor immune activation and PD-L1 blockade. Our strategy offers a simple but promising approach for the treatment of metastatic cancer.
Insights
This study introduces a novel nanoparticle for cancer immunotherapy. The nanoparticle combines photothermal therapy and PD-1/PD-L1 blockade to enhance antitumor immunity and treat metastatic cancers effectively.
Area of Science:
- Biomedical Engineering
- Immunotherapy
- Nanotechnology
Background:
- Checkpoint inhibitors targeting the PD-1/PD-L1 pathway show promise for metastatic cancers but have low response rates and drawbacks.
- Monoclonal antibodies used as checkpoint inhibitors present certain limitations in cancer treatment.
Purpose of the Study:
- To develop a versatile, all-synthetic nanoparticle for combined photothermal therapy and PD-1/PD-L1 blockade.
- To enhance the efficacy of cancer immunotherapy by integrating multiple treatment modalities into a single system.
Main Methods:
- Fabrication of a polymeric nanoparticle capable of PD-L1 blockade.
- Integration of photothermal treatment, antitumor vaccination, and PD-1/PD-L1 blockade within the nanoparticle system.
- Evaluation of the nanoparticle's efficacy in a CT26 bilateral tumor model using intravenous injection.
Main Results:
- Intravenously injected nanoparticles effectively accumulated in tumor sites.
- The nanoparticles induced significant photothermal effects, eradicating primary tumors treated with near-infrared (NIR) light.
- Systemic antitumor immune activation and PD-L1 blockade led to the suppression of untreated distant tumors, demonstrating efficacy against metastatic cancer.
Conclusions:
- The developed nanoparticle system offers a potent strategy for cancer photothermal-immunotherapy.
- This integrated approach augments antitumor efficacy by combining photothermal effects, immunogenic cell death, and PD-1/PD-L1 blockade.
- The strategy presents a promising and simplified method for treating metastatic cancers.
